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Mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause late-onset Parkinson’s disease, but its
physiological function has remained largely unknown. Here we report that LRRK2 activates a calcium-depen-
dent protein kinase kinase-b (CaMKK-b)/adenosine monophosphate (AMP)-activated protein kinase (AMPK)
pathway which is followed by a persistent increase in autophagosome formation. Simultaneously, LRKR2
overexpression increases the levels of the autophagy receptor p62 in a protein synthesis-dependent
manner, and decreases the number of acidic lysosomes. The LRRK2-mediated effects result in increased
sensitivity of cells to stressors associated with abnormal protein degradation. These effects can be mimicked
by the lysosomal Ca
21-mobilizing messenger nicotinic acid adenine dinucleotide phosphate (NAADP) and
can be reverted by an NAADP receptor antagonist or expression of dominant-negative receptor constructs.
Collectively, our data indicate a molecular mechanism for LRRK2 deregulation of autophagy and reveal
previously unidentiﬁed therapeutic targets.
INTRODUCTION
Autosomal-dominant mutations in leucine-rich repeat kinase 2
(LRRK2) cause late-onset familial Parkinson’s disease (PD)
(1,2) which is symptomatically and neurochemically indistin-
guishable from sporadic PD. In addition, pathogenic mutations
contribute to sporadic PD and variations increase risk for PD,
suggestingthatLRRK2maybeanimportantfactorforidiopath-
ic disease progression as well (3). The most prominent patho-
genic LRRK2 mutation (G2019S), located within the kinase
domain, has been consistently shown to enhance kinase activity
in vitro (4–7), suggesting that it may display a dominant,
gain-of-function phenotype. Overexpression of LRRK2 har-
bouringthisdisease-segregatingmutationleadstoneurotoxicity
invivo, and such neurotoxicity is linked tothe kinase activity of
LRRK2 (8–11). Thus, the pathogenic role of mutant LRRK2
seems to be dependent on catalytic activity.
Overexpression of G2019S-mutant LRRK2 in neuronal
cells decreases neurite process length with a concomitant
accumulation of autophagic structures (12–14), and an
impaired autophagic balance is also observed upon overex-
pression of LRRK2 in non-neuronal and yeast cells (15,16).
This is in agreement with the ﬁndings that a signiﬁcant
portion of endogenous LRRK2 is localized to membranous
structures including ER and endosomal–lysosomal compart-
ments (17), and implicates LRRK2 as an important regulator
of macroautophagy.
Macroautophagy (hereafter referred to as autophagy) is a
process whereby cytoplasmic constituents are engulfed within
specialized double-membrane vesicles called autophagosomes,
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Autophagy normally proceeds at a low, basal rate, which
plays a key role in the homeostatic clearance of old or
damaged organelles and proteins (18,19). Basal autophagy is
especially highinneuronal cells,and neurons undergo degener-
ation when basal autophagic degradation is disrupted (20,21).
Autophagic failure seems to underlie a variety of neurodegen-
erative diseases (22), and deregulation of autophagy is evident
in the brains of PD patients (23).
Despite the ﬁndings linking LRRK2 to deregulated autop-
hagy, the exact mechanisms underlying such deregulation
have not been characterized. In this work, we ﬁnd that overex-
pression of LRRK2 causes an increase in autophagy induction
through Ca
2+-dependent activation of a CaMKK/adenosine
monophosphate (AMP)-activated protein kinase (AMPK)
pathway, which can be inhibited by calcium chelation or
ectopic Bcl-2. At the same time, LRRK2 causes a partial
increase in lysosomal pH and a decrease of cell survival in
the presence of protein aggregation-induced stress. The
LRRK2-mediated effects involve activation of nicotinic acid
adenine dinucleotide phosphate (NAADP)-sensitive two-pore
channels (TPCs) located on acidic stores, and can be
blocked by a speciﬁc antagonist. Together, our data indicate
a molecular mechanism by which LRRK2 may act to regulate
lysosomal Ca
2+ homeostasis, with downstream effects on
autophagy as well as other Ca
2+-dependent cellular events.
RESULTS
LRRK2 overexpression causes autophagy induction
To study the effect of LRRK2 on basal autophagy, we selected
a variety of constructs including full-length LRRK2 (ﬂ-kinase)
and variants bearing the pathogenic G2019S mutation
(ﬂ-G2019S) or the kinase-inactivating K1906M mutation
(ﬂ-K1906M), respectively. To evaluate whether effects are
due to the kinase domain and activity of LRRK2 (12), we
also used the kinase domain (kinase) or variants therof
(G2019S, K1906M) on their own, respectively. Overexpressed
proteins were mostly cytosolic, wild-type (WT) and mutant
proteins displayed similar overexpression levels, and no cellu-
lar toxicity was apparent 24 or 48 h upon transfection, as
previously described (10) (Supplementary Material, Fig. S1).
We next addressed the effects of LRRK2 overexpression on
autophagosome formation. LC3 is the mammalian homologue
of the yeast Atg8 protein, which is covalently modiﬁed and
re-distributes to autophagic vacuoles during induction of
autophagy (23). This process can be followed by the appear-
ance of LC3 puncta or ring-like structures and by a mobility
shift from LC3I to LC3II by SDS–PAGE. Cells transiently
transfected with LC3–GFP alone, or co-transfected with
empty vector and analysed 48 h after transfection, display
few cytoplasmic LC3–GFP punctae (Fig. 1A and B). An
increase in LC3–GFP punctae was observed when
co-transfecting with full-length wild-type as well as with
G2019S-mutant LRRK2, but not with the inactive K1906M
mutant (Fig. 1B). A similar increase in LC3–GFP punctae
was observed with wild-type or G2019S-mutant, but not
K1906M-mutant kinase domain only (Fig. 1A and B), indicat-
ing that the effects on autophagy are, at least in part, due to the
kinase domain and activity of LRRK2. Wild-type and
G2019S-mutant full-length LRRK2 increased autophagosome
numbers to a similar degree and comparable with that of
wild-type or G2019S-mutant kinase domain only (Fig. 1B),
possibly due to saturating levels of overexpression of the
various active constructs with respect to downstream targets.
As a positive control, inhibition of the mammalian target of
rapamycin (mTOR) protein kinase by rapamycin was found to
induce autophagy to a similar degree (Fig. 1B). The phospha-
tidylinositol 3-kinase inhibitor 3-methyladenine (3-MA) is
thought to suppress autophagy by inhibiting the production
of phosphatidylinositol-3-phosphate required for autophago-
some formation (24), and was found to block the increase in
autophagosome numbers mediated by rapamycin, but not by
LRRK2 overexpression (Fig. 1B). Such differential 3-MA sen-
sitivity has previously been described (13), and points towards
a possible mechanistic difference between mTOR- and
LRRK2-mediated autophagy induction. An increase in autop-
hagosome numbers was further reﬂected by an increase in the
level of endogenous LC3II (Fig. 1C), and transmission elec-
tron microscopy conﬁrmed that the induction of LC3-positive
vesicles by LRRK2 overexpression correlated with an increase
in the number of autophagic structures (Fig. 1D and E).
We next used a pH-sensitive tagged LC3 construct consist-
ing of a tandem fusion of the red, acid-insensitive mCherry
(pKa , 4.5) and the acid-sensitive GFP (pKa 6.0)
(td-tag-LC3) (25,26). Td-tag-LC3 will emit yellow (green
merged with red) ﬂuorescence in non-acidic structures, but
appear as red only in autolysosomes due to the quenching of
GFP in these acidic structures (25,26). Indeed, td-tag-LC3
was found to faithfully track autophagosome maturation in
transfected cells, thus allowing for the identiﬁcation of
possible deﬁcits in autophagic maturation (Supplementary
Material, Fig. S2). Co-transfection of td-tag-LC3 with
G2019S-mutant LRRK2 kinase domain increased both early
and late autophagic structures (Fig. 2A and B). Such increase
in both yellow and red punctae was also observed with wild-
type kinase domain or with full-length LRRK2, but not with
the catalytically inactive K1906M mutant (Fig. 2B). As a posi-
tive control for blocking autophagosome maturation, we used
trichostatin A, an inhibitor of histone deacetylases (HDACs)
known to be required for the fusion of autophagosomes with
lysosomes (27). Indeed, trichostatin A treatment signiﬁcantly
increased the percentage of yellow punctae (and decreased
the number of red punctae), in contrast to LRRK2 expression
or autophagy induction by rapamycin (Fig. 2C and D). These
data indicate that LRRK2 overexpression enhances autopha-
gosome numbers and at least the initial steps of autophago-
some maturation in a manner dependent on kinase activity.
LRRK2 overexpression activates the Ca
21/CaMKK/
AMPK pathway
The increase in autophagosome numbers probably results from
cytosolic events regulated by LRRK2. As recent studies imply
an important role for AMPK in basal autophagy regulation
(28), we evaluated the effects of LRRK2 on AMPK activity.
Expression of wild-type and G2019S-mutant LRRK2 kinase
domain, but not its inactive mutant, increased AMPK activity
(Fig. 3A and B). This was not accompanied by inhibition of
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ment(Fig.3CandDandSupplementaryMaterial,Fig.S3)(29).
Accordingly, inhibition of AMPK by a pharmacological
inhibitor(compoundC)(30)attenuatedtheincreaseinautopha-
gosome numbers induced by LRRK2 kinase domain overex-
pression (Fig. 3E). Compound C also attenuated the increase
in autophagosome numbers observed with ionomycin and
ATP, two treatments previously shown to activate AMPK
(31), but was without effect on autophagosome numbers
induced by rapamycin (Fig. 3E).
Further evidence for an involvement of AMPK was gained
by expressing wild-type, dominant-negative and constitutively
active forms of this kinase (32). Wild-type and mutant
AMPKa1 forms were overexpressed to similar degrees and
without effect on cellular viability, with AMPKa2 forms
expressed to a lesser degree and displaying cellular toxicity
(Supplementary Material, Fig. S4). Expression of wild-type
and constitutively active, but not dominant-negative,
AMPKa1 induced an increase in autophagosome numbers
(Fig. 4A). Importantly, the dominant-negative AMPKa1
Figure 1. Effects of LRRK2 overexpression on autophagosome formation. (A) Example of HEK293T cells transfected with LC3–GFP and either empty vector
(ctrl), catalytically inactive K1906M-mutant LRRK2 kinase domain (K1906M), wild-type LRRK2-kinase domain (kinase) or catalytically hyperactive
G2019S-mutant LRRK2 kinase domain (G2019S). LC3–GFP ﬂuorescence (green) and nuclear DAPI staining (blue). Scale bar, 10 mm. (B) Quantiﬁcation of
the number of LC3–GFP punctae per cell in the absence (white bars) or the presence of 3-MA (5 mM, 24 h) (grey bars). Cells were co-transfected with
LC3–GFP and the indicated constructs, and LC3–GFP punctae quantiﬁed 48 h after transfection. Rapamycin (100 nM, 12 h) was used as positive control.
Bars represent mean+s.e.m. (n ¼ 4); ∗P , 0.001. (C) Top: cells were transfected with either K1906M or kinase constructs, and extracts analysed for endogen-
ous LC3I and LC3II blotting with an anti-LC3 antibody (Cell Signalling). Bottom: quantiﬁcation of LC3II/tubulin from different experiments (mean+s.e.m.
(n ¼ 3); ∗P , 0.05. (D) Representative electron micrographs of cells expressing LRRK2 kinase domain. Arrows point to distinct autophagic structures [scale bar
200 nm (left) or 500 nm (right)]. (E) Cells were co-transfected with EGFP and empty vector (GFP) or kinase domain (kinase), and FACS sorted before process-
ing for electron microscopy. Stereological analysis of the number of intersections per cell, number of intersections per autophagic structures (AVs), percentage of
cellular volume occupied by AVs and AV diameter were quantiﬁed from three individual cells per condition. ∗P , 0.05.
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numbers observed upon active LRRK2 kinase domain
co-expression (Fig. 4B). Such inhibition was not observed
when autophagic on-rate was increased by distinct means, in-
dicating a speciﬁc involvement of the AMPK pathway in the
LRRK2-mediated process (Supplementary Material, Fig. S4).
AMPK can be activated by CaMKK-b in response to an
increase in the cytosolic-free calcium [Ca
2+]c (31). In order
to test whether LRRK2 expression regulates the Ca
2+/
CamKK-b/AMPK pathway, we ﬁrst treated cells with a
CaMKK-a/b inhibitor (STO-609) (33). This compound
attenuated the increase in autophagosome formation induced
by LRRK2 kinase domain (Fig. 4C). Such inhibition was
similar to that observed when cells were treated with two
stimuli which increase [Ca
2+]c by distinct means: ATP,
which acts on P2 purinoreceptors to generate inositol
1,4,5-triphosphate (IP3) that triggers the release of Ca
2+
from the ER through IP3 receptor-regulated channels, or iono-
mycin, a Ca
2+ ionophore that serves as a mobile Ca
2+ carrier
to equilibrate Ca
2+ levels across biological membranes,
including plasma and ER membranes (31,34,35) (Fig. 4C).
In contrast, the CaMKK-a/b inhibitor had no effect on
Figure 2. Effects of LRRK2 overexpression on autophagosome maturation. (A) Example of HEK293T cells co-transfected with tandem-tagged-LC3
(td-tag-LC3) and either empty vector (pCMV) or G2019S-mutant LRRK2 kinase domain. White: co-localization mask to highlight yellow punctae. Scale
bar, 10 mm. (B) Quantiﬁcation of the number of early, yellow-only td-tag-LC3 punctae per cell (top), or the overall ﬂuorescence from late, red-only
td-tag-LC3 punctae per cell (bottom). Cells were co-transfected with td-tag-LC3 and either empty pCMV vector (ctrl), wild-type or mutant kinase or full-length
LRRK2 kinase (ﬂ-kinase) constructs as indicated, and quantiﬁed 48 h after transfection. Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.05. (C) Example of cells
co-transfected with td-tag-LC3 and LRRK2 kinase domain, or transfected with td-tag-LC3 and treated with trichostatin A (300 nM, 4 h). White: co-localization
mask to highlight yellow punctae. Scale bar, 10 mm. (D) Quantiﬁcation of the percentage of early, yellow td-tag-LC3 punctae per cell. Cells were co-transfected
with td-tag-LC3 and either kinase or empty vector. The latter were either left untreated (ctrl), or treated with rapamycin (rap.; 100 nM, 4 h) or trichostatin A
(tricho.; 300 nM, 4 h) prior to ﬁxation. Note that the percentage of yellow punctae in trichostatin-treated cells is increased because of the decrease in the
number of red punctae. Bars represent mean+s.e.m. (n ¼ 2); ∗P , 0.05.
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(Fig. 4C). Remarkably, addition of the intracellular Ca
2+ che-
lator BAPTA-AM (bis-(O-aminophenoxy)-ethane-N,N,N,N′-
tetraacetic acid/tetra(acetoxymethyl)-ester) to LRRK2 kinase
domain or full-length LRRK2-transfected cells for the last 2
hours completely abolished the increase in autophagosome
numbers (Fig. 4D). BAPTA-AM was further able to block
the ionomycin-mediated, but not the rapamycin-mediated,
increase in autophagosome numbers (Supplementary Material,
Fig. S4). Thus, a Ca
2+/CaMKK/AMPK pathway seems to be
required for the increased formation of autophagosomes in
response to active LRRK2 overexpression.
ER-localized Bcl-2 inhibits LRRK2-mediated autophagy
induction
Bcl-2 has been reported to regulate cellular Ca
2+ handling
and Ca
2+/CaMKK/AMPK-induced autophagy (31,36). Thus,
we tested whether expression of bcl-2 could inhibit the
LRRK2-mediated increase in autophagosome numbers via
its effects on Ca
2+ homeostasis. For this purpose, we
expressed wild-type bcl-2 (Bcl-WT), which is mostly mito-
chondrial (36,37), or mutants in which the C-terminal hydro-
phobic sequence has been either removed (Bcl-cyt), resulting
in cytosolic expression, or exchanged to a corresponding
membrane anchor from an ER-speciﬁc isoform of cyto-
chrome b5 (Bcl-ER) or L. monocytogenes ActA (Bcl-mito),
resulting in distinct subcellular localizations (31,38).
Western blot analysis conﬁrmed equal expression levels,
and only slight effects on cytotoxicity were observed when
overexpressing Bcl-wt or Bcl-mito, but not Bcl-cyto or
Bcl-ER, respectively (Supplementary Material, Fig. S4).
Importantly, only Bcl-ER was able to fully inhibit the
LRRK2 kinase domain-mediated increase in autophagosome
numbers (Fig. 4E). ER-localized Bcl-2 has previously been
demonstrated to lower [Ca
2+]ER and agonist-induced Ca
2+
leak from the ER (39). Together with the inhibitory effect
of BAPTA-AM and inhibition of CaMKK on the LRRK2-
mediated increase in autophagosome numbers, these results
indicate that active LRRK2 may increase [Ca
2+]c by directly
or indirectly inducing Ca
2+ release from the ER. This release
is likely mediated by IP3 receptors, as the increase in auto-
phagosome numbers upon LRRK2 expression could not be
blocked by dantrolene, a ryanodine receptor antagonist
(Supplementary Material, Fig. S4).
LRRK2 alkalinizes a subpopulation of lysosomes
Overexpression of LRRK2 has previously been shown to lead
to accumulation of multi-vesicular bodies and autophago-
somes containing incompletely degraded material and p62
(15), a classical macroautophagy substrate (40), indicating
possible defects in autophagic degradation. Indeed, overex-
pression of wild-type or G2019S-mutant, but not inactive
K1906M-mutant, kinase domain led to a signiﬁcant increase
in p62 levels and p62-positive structures (Fig. 5A–C).
Figure 3. Effects of LRRK2 overexpression on AMPK and TORC1 signalling. (A) HEK293T cells were transfected with either empty vector (ctrl) or indicated
constructs, and cell extracts analysed for phospho-ACC, phospho-AMPK and AMPK. (B) Quantiﬁcation of the type of experiments depicted in (A). Bars rep-
resent mean+s.e.m. (n ¼ 3); ∗P , 0.05. (C) As in (A), but extracts analysed for the indicated TORC1 substrates. (D) Quantiﬁcation of the type of experiments
depicted in (C). Bars represent mean+s.e.m. (n ¼ 3). (E) Cells were co-transfected with LC3–GFP and either empty vector (ctrl) or LRRK2 kinase domain, and
control-transfected cells were treated with rapamycin (100 nM, 12 h), ionomycin (2.5 mM, 12 h) or ATP (100 mM, 12 h) where indicated. Cells were incubated in
the absence (white bars) or the presence (grey bars) of compound C (5 mM, 24 h), and LC3–GFP punctae quantiﬁed 48 h after transfection. Bars represent
mean+s.e.m. (n ¼ 3); ∗P , 0.05.
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be blocked by protein synthesis inhibitors (Fig. 5D), indicating
that it was not reﬂecting changes in autophagic ﬂux. Identical
results were obtained when using ionomycin or thapsigargin
(Supplementary Material, Fig. S5), suggesting that the
LRRK2-mediated effects on p62 levels may be due to Ca
2+-
dependent changes in protein synthesis (41).
A possible defect in lysosomal homeostasis, however,
became apparent when employing lipid staining with
BODIPY 493/503 (42), which revealed an increase in lipid
droplet numbers in cells overexpressing LRRK2 kinase
domain (Fig. 6A and B). In addition, lysotracker DND-99 or
Lysosensor staining to determine lysosomal pH indicated a
decrease in the number of positive punctae in cells overexpres-
sing active LRRK2 kinase domain (Fig. 6C and D). This was
not due to a decrease in lysosomal content (43), as no change
in the levels of LAMP1 or LAMP2 were observed (Supple-
mentary Material, Fig. S6). Interestingly, quantiﬁcation of
the percent colocalization of LAMP2 and lysotracker
showed an increase in the number of structures positive for
LAMP2, but negative for lysotracker, suggesting that
LRRK2 increases pH in a subpopulation of lysosomes,
without affecting the processing of lysosomal hydrolases
(Fig. 6E and Supplementary Material, Fig. S6).
LRRK2 acts through NAADP receptors
There is considerable evidence that acidic organelles such as
endosomes and lysosomes are signiﬁcant stores of Ca
2+ that
can be released by the Ca
2+ mobilizing messenger NAADP
(44,45). NAADP-evoked cytosolic Ca
2+ signals are accom-
panied by partial alkalinization of acidic stores (46) and amp-
liﬁcation by ER Ca
2+ stores (47), and lysosomal Ca
2+
depletion causes lipid accumulation (48). That LRRK2
increases lipid droplet numbers (Fig. 6), causes an increase
in lysosomal pH (Fig. 6) and regulates Ca
2+-dependent
events in the cytosol which likely also involve the ER
(Figs. 4 and 5) prompted us to consider the involvement of
the NAADP pathway in mediating the effects of LRRK2.
Application of NAADP-AM was found to increase autopha-
gosome numbers (Fig. 6F). This increase was abolished at
higher NAADP concentrations, in agreement with the notion
that NAADP-induced Ca
2+ release desensitizes at high
ligand concentrations (49,50). The effect of NAADP on auto-
phagosome formation could be blocked by BAPTA-AM
(Fig. 6F) and was accompanied by an increase in AMPK activ-
ity (Supplementary Material, Fig. S6). The autophagy induc-
tion observed with NAADP could be inhibited by Bcl-ER
(Fig. 6G), similar to starvation-induced autophagy (36,37),
Figure 4. Effects of LRRK2 overexpression on AMPK and intracellular calcium. (A) HEK293T cells were co-transfected with LC3–GFP and either empty
vector (ctrl), human wild-type AMPKa1 (1-wt), dominant-negative (1-DN) or constitutively active (1-CA) AMPKa1, and LC3–GFP punctae quantiﬁed
48 h after transfection. Rapamycin (100 nM, 12 h) (rap.) was used as control. Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.05. (B) Cells were transfected
with LC3–GFP along with either empty vector (ctrl), or LRRK2 kinase domain (kin) in the presence or in the absence of wild-type (1-wt) or dominant-negative
(1-DN) AMPKa1 constructs as indicated, and LC3–GFP punctae quantiﬁed 48 h after transfection. Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.01. (C) Cells
were co-transfected with LC3–GFP and either empty vector (ctrl) or LRRK2 kinase domain (kinase), and control-transfected cells were treated with rapamycin
(100 nM, 12 h), ionomycin (2.5 mM, 12 h) or ATP (100 mM, 12 h) where indicated. Cells were incubated in the absence (white bars) or in the presence (grey bars)
of STO-609 (20 mM, 24 h), a CaMKKb inhibitor and LC3–GFP punctae quantiﬁed 48 h after transfection. Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.05. (D)
Cells were co-transfected with LC3–GFP and either empty vector (ctrl) or the indicated wild-type or mutant kinase domain or full-length (ﬂ) constructs, and
either left untreated (white bars) or treated with BAPTA-AM (5 mM, 2 h) (grey bars) prior to analysis for LC3–GFP punctae 48 h after transfection. Bars rep-
resent mean+s.e.m. (n ¼ 3); ∗P , 0.05. (E) Cells were transfected with LC3–GFP along with either K1906M mutant (white bars) or wild-type (grey bars)
LRRK2 kinase domain and either control empty vector (2) or the indicated chimeric Bcl constructs, and LC3–GFP punctae analysed 24 h after transfection.
Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.05.
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treatment (Fig. 6G). In addition, the autophagy induced by
NAADP was insensitive to 3-MA, in contrast to TORC1-
dependent autophagy inducers (Fig. 6H). Furthermore,
NAADP caused an increase in LC3II levels (Fig. 6I), a
protein synthesis-dependent increase in p62 levels (Fig. 6J),
increased lipid droplet numbers (Fig. 6K) and increased lyso-
somal pH (Fig. 6L), thus fully mimicking the effects of
LRRK2 expression.
TPCs have recently emerged as the likely targets for
NAADP, with TPC1 localized to both endosomes and lyso-
somes, and TPC2 mainly to lysosomes (50,51). Point
mutants in the putative helix of the pore-forming regions
have been described, which seem to largely abolish Ca
2+ con-
ductance and uncover dominant-negative effects with respect
to NAADP-mediated Ca
2+ signals (51,52). Thus, we evaluated
whether co-expressing wild-type or mutant TPCs may inter-
fere with LRRK2-mediated autophagosome formation. Ex-
pression of mRFP-tagged TPC constructs indicated that
wild-type and mutant versions were similarly overexpressed
and localized to intracellular compartments, with TPC2 par-
tially co-localizing with the lysosomal marker LAMP2, as pre-
viously described (51). None of the TPC constructs displayed
cytotoxicity at 24 h upon overexpression, but TPC1 and its
mutant were found to increase autophagosome formation
(Supplementary Material, Fig. S7). Whilst consistent with
the involvement of TPC1 in endolysosomal trafﬁcking (53),
this ﬁnding precluded further analysis of a possible reversal
of the LRRK2-mediated increase in autophagosome numbers
by TPC1 constructs. In contrast, TPC2 and its mutant did
not display effects on autophagosome numbers when
expressed on their own (Fig. 7A). Importantly, mutant but
not wild-type TPC2 was able to block the effect of LRRK2
kinase domain on autophagosome numbers (Fig. 7A).
We next evaluated whether NED-19, a newly described
NAADP antagonist (54), could reverse the LRRK2-mediated
effects on autophagic ﬂux. NED-19 on its own was without
effect on autophagosome numbers, but could block the in-
crease in autophagosome numbers mediated by active kinase
domain or full-length LRRK2 (Fig. 7B). This was accompan-
ied largely by a reversal in the LRRK2-mediated changes
on AMPK activity (Supplementary Material, Fig. S7), p62
levels, LC3II levels and lysotracker-positive structures
(Fig. 7C–E). Finally, when probing for an interaction
between endogenous LRRK2 and GFP–TPC2, LRRK2 was
found to co-immunoprecipitate with GFP–TPC2 and vice
versa (Fig. 7F and Supplementary Material, Fig. S7).
Together, these data indicate that NAADP mimicks the
effects of active LRRK2, whilst NED-19 application can
revert those effects, and suggest that NAADP receptors may
be direct targets for regulation by LRRK2.
LRRK2 sensitizes cells to cell death induced by proteasome
inhibition
As the observed LRRK2-mediated effects were not cytotoxic
per se, we next wondered whether they would sensitize cells
towards cell death under certain conditions (55). When cells
were treated with the proteasomal inhibitor MG-132, cell
death was markedly accelerated in cells overexpressing
active, but not inactive, LRRK2 kinase domain (Fig. 8A).
The increased cell death in the presence of MG-132 in
LRRK2 kinase domain-expressing cells could be blocked by
NED-19 (Fig. 8B), supporting the involvement of the
NAADP pathway in this process. Interestingly, application
of rapamycin or torin, two speciﬁc TORC1 inhibitors, reverted
the LRRK2-mediated effects on cell death in the presence of
MG-132, whilst L690,440, a TORC1-independent auto-
phagy-enhancing compound (56), was unable to do so
(Fig. 8A and C). Rapamycin and torin also largely reversed
the effects of LRRK2 on p62 accumulation and on the
decrease in lysotracker staining (Fig. 8D and E). Measurements
Figure 5. Effects of LRRK2 overexpression on p62 levels. (A) HEK293T cells were transfected with either control empty vector (ctrl) or wild-type or mutant
kinase domain constructs as indicated, and extracts analysed for endogenous p62 levels. (B) Quantiﬁcation of the type of experiments as depicted in (A). Bars
represent mean+s.e.m. (n ¼ 3); ∗P , 0.05. (C) Example of cells co-transfected with LC3–GFP (green, left) and LRRK2 kinase domain and co-stained with
anti-p62 (red, middle). Scale bar, 10 mm. (D) Cells were transfected with indicated constructs, and treated with puromycin (1 mM, 6 h) where indicated before
analysis and quantiﬁcation of p62 levels. Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.05.
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results. The NAADP-receptor antagonist NED-19 was able
to revert the LRRK2-mediated increase in autophagosome
numbers, the LRRK2-mediated decrease in lysosensor-
positive structures and the LRRK2-mediated increase in cell
death in the presence of MG-132 (Supplementary Material,
Fig. S8). Together, these data indicate that additional interfer-
ence with proteasomal degradation is detrimental to cells over-
expressing catalytically active LRRK2, and that blocking
NAADP-mediated signalling, or enhancing autophagic ﬂux
Figure 6. Effects of LRRK2 on lipid accumulation and lysosomal pH, and effects of NAADP. (A) Example of HEK293T cells co-transfected with mCherry and
either K1906M-mutant or wild-type LRRK2 kinase domain, and stained with BODIPY 493/503 (green). Scale bar, 10 mm. (B) Percentage change in the number
of lipid droplets quantiﬁed from experiments as in (A). Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.005. (C) The number of lysosensor-positive structures in
cells expressing K1906M or kinase domain. Bars represent mean+s.e.m. (n ¼ 4); ∗P , 0.05. (D) Percentage change in the number of lysotracker-positive struc-
tures in cells co-transfected with EGFP and either K1906M or kinase domain constructs. Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.005. (E) Quantiﬁcation of
LAMP2-positive structures positive for lysotracker in K1906M or kinase-expressing cells. Ten random cells were analysed per condition per experiment. Bars
represent mean+s.e.m. (n ¼ 2); ∗P , 0.05. (F) Cells were transfected with LC3–GFP and either left untreated, or treated with the indicated concentrations of
NAADP-AM or with 1 mM NED-19 for 12 h, in the absence (white bars) or in the presence (grey bars) of BAPTA-AM (5 mM, 2 h), and LC3–GFP punctae
quantiﬁed 48 h after transfection. Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.005. (G) Cells were co-transfected with LC3–GFP and either control empty
vector (white bars) or bcl-ER (grey bars), and either left untreated (ctrl), treated with NAADP-AM (100 nM, 4 h), starvation (Earle’s salt solution, 4 h), rapamycin
(200 nM, 4 h) or torin (50 nM, 4 h) as indicated, and LC3–GFP punctae analysed 24 h after transfection. Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.05. (H)
Cells were transfected with LC3–GFP and either left untreated (ctrl), or treated with NAADP-AM (100 nM, 12 h) or rapamycin (100 nM, 12 h) as indicated in the
presence or in the absence of 3-MA (5 mM, 24 h) (grey bars). Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.05. (I) Cells were either left untreated, or treated with
NAADP-AM (100 nM, 12 h) as indicated, and cell extracts analysed and quantiﬁed for endogenous LC3. Bars represent mean+s.e.m. (n ¼ 2); ∗P , 0.05. (J)
Cells were left untreated or treated with NAADP-AM (100 nM, 12 h) or puromycin (1 mM, 6 h) as indicated, and extracts analysed and quantiﬁed for p62 levels.
Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.05. (K) Non-treated or NAADP-AM-treated cells were stained with BODIPY 493/503 and analysed for the per-
centage change in the number of lipid droplets. Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.01. (L) Non-treated or NAADP-AM-treated cells were stained with
lysotracker and the percentage change quantiﬁed. Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.005.
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homeostasis through a TORC1-dependent pathway can over-
come the enhanced susceptibility to cell death induced by
LRRK2 in non-neuronal as well as neuroendocrine cells.
DISCUSSION
Mutations in LRRK2 are the most common genetic cause of
PD, but the function of the protein remains unknown. Our
study provides insight into the molecular mechanism of
LRRK2 action. We have shown that LRRK2 kinase activity
exerts a previously unknown regulatory role on macroauto-
phagy that seems to involve Ca
2+ release from lysosomes
and the Ca
2+/CaMKK/AMPK pathway. These events seem
to be mediated by activation of NAADP receptors, which
causes Ca
2+ efﬂux from acidic stores and is accompanied by
a partial alkalinization of lysosomal store pH (Fig. 9).
In our experimental conditions, wild-type LRRK2 had a sig-
niﬁcant effect similar to pathogenic G2019S-mutant LRRK2.
As mutations in LRRK2 cause PD in an autosomal-dominant
manner, we overexpressed the protein to mimic a gain-
of-function phenotype. It is feasible that the pathogenic mech-
anism of LRRK2 depends on exceeding a threshold level of
activity, also supported by the ﬁnding that homo- and hetero-
zygous carriers of LRRK2 mutations are clinically indistin-
guishable (3). In this context, overexpressing both wild-type
or G2019S-mutant LRRK2 may reach the threshold level
required for LRRK2 function and/or activity to become patho-
genic. Alternatively, we may have missed a small but bio-
logically important difference in effect, which nevertheless
may have important consequences when present over many
years. Finally, it remains possible that the effects described
here are a wild-type function of LRRK2 unrelated to PD,
even though other studies describing an impaired autophagic
balance with G2019S-mutant, but not wild-type LRRK2
(12–16), are consistent with the idea of a threshold effect.
Previous studies have indicated that enhanced autophagy
may mediate neurite shortening induced by G2019S LRRK2
expression, as molecular inhibition of autophagy reversed,
and pharmacological activation of autophagy potentiated the
effects of LRRK2 on neurite shortening (12,13). Whilst our
data are consistent with the notion that LRRK2 expression
causes autophagy induction, we ﬁnd that pharmacological
Figure 7. A link between LRRK2 and NAADP-sensitive receptors. (A) HEK 293T cells were transfected with LC3–GFP along with K1906M-mutant or wild-
type kinase domain and either empty vector (pCMV), TPC2 or mutant TPC2 as indicated, and LC3–GFP punctae quantiﬁed 24 h after transfection. Bars rep-
resent mean+s.e.m. (n ¼ 5); ∗P , 0.005. (B) Cells were co-transfected with LC3–GFP and the indicated kinase domain or full-length (ﬂ) LRRK2 constructs,
and either left untreated (white bars) or treated with NED-19 (1 mM, 12 h) (grey bars), followed by quantiﬁcation of LC3–GFP punctae 48 h after transfection.
Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.005. (C) Transfected cells were treated with NED-19 (1 mM, 12 h) where indicated before analysis for p62 levels.
Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.05. (D) As in (C), but extracts analysed and quantiﬁed for LC3II levels. Bars represent mean+s.e.m. (n ¼ 3);
∗P , 0.05. (E) Transfected cells were treated with NED-19 (1 mM, 12 h) where indicated before staining with lysotracker. Bars represent mean+s.e.m.
(n ¼ 4); ∗P , 0.05. (F) Cells were transfected with TPC2–GFP or GFP vector, and extracts (1 mg) subjected to immunoprecipitation with an anti-GFP antibody.
Note that TPC2–GFP runs as distinct bands corresponding to core glycosylated and mature fully glycosylated versions, respectively (67).
Co-immunoprecipitated endogenous LRRK2 was detected using an anti-LRRK2 antibody (MJFF2, Epitomics). Note the additional presence of lower molecular-
weight bands, which are likely distinct degradation products of endogenous LRRK2. Inputs (5%) were run along-side the immunoprecipitates. Representative of
a total of seven independent experiments.
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dictory to the aggravating effects of rapamycin on neurite
length (13). However, the micromolar, but not nanomolar,
concentrations of rapamycin employed in this study (13)
leave open the possibility of secondary effects unrelated to
TORC1 inhibition. In addition, even though neurite length
and complexity may be relevant readouts for the cellular
effects of LRRK2, enhanced stress sensitivity and cell death
are equally informative for our understanding of LRRK2 func-
tion in cultured cells (55). The observed effects of LRRK2 are
not sufﬁcient to cause cell death, but increase the susceptibility
of cells to further insults related to protein degradation-
mediated stress, reminiscent of data obtained with LRRK2/
a-synuclein double-transgenic mice (57). In addition, trans-
genic mice expressing G2019S-mutant LRRK2 display
progressive age-dependent degeneration of dopaminergic
neurons in vivo, accompanied by the accumulation of autopha-
gic structures (14). These data imply an important regulatory
role for LRRK2 in autophagic balance, which leads to even-
tual cell death in the presence of an additional trigger.
LRRK2 overexpression induces the formation of
autophagosomes through a Ca
2+/CaMKK/AMPK pathway.
Contradictory data have emerged as to the role of cytosolic
Ca
2+ and autophagy, with both stimulatory (31) and inhibitory
(56) effects on autophagy. Our data indicate that Ca
2+ displays
complex effects at different stages of the pathway, and is
required in distinct intracellular locations. In this context, it
is interesting to note that LRRK2 or reagents which increase
intracellular Ca
2+ were both found to increase p62 protein
synthesis, indicating that, apart from regulation of autophagy,
the LRRK2-mediated change in cytosolic Ca
2+ may, at least in
part, underlie some of the protein synthesis-mediated events
proposed for LRRK2 (58,59).
The effects of LRRK2 on autophagy induction were found
to be TORC1 independent, in agreement with recent ﬁndings
that autophagy under normal nutritional conditions is
TORC1 independent and regulated by AMPK and InsP3-
R-mediated Ca
2+ signalling from the ER (28,56,60). Further-
more, the LRRK2-mediated sensitization to cell death in the
presence of proteasomal inhibition could be reversed by
TORC1 inhibitors. Such reversal may be due to an increase
in degradative capacity as autophagic ﬂux is enhanced, a de-
crease in protein synthesis, an effect on lysosomal homeostasis
(61) or a combination thereof. Indeed, evidence for all three
Figure 8. Effects of LRRK2 expression on cellular viability in the presence of proteasomal inhibitor. (A) HEK293T cells were co-transfected with GFP and
K1906M or kinase domain constructs as indicated and either left untreated (2), treated with rapamycin (100 nM, 4 h), MG-132 (500 nM, 12 h) or both as indi-
cated. Cells were analysed for cell death 48 h after transfection using Hoechst staining. Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.005. (B) As in (A), but
cells treated with NED-19 (1 mM, 12 h) as indicated. Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.005. (C) As in (A), but cells treated with torin (500 nM, 4 h) or
L690,440 (10 mM, 4 h) as indicated. Bars represent mean+s.e.m. (n ¼ 3); ∗P , 0.005. (D) Left: cells were transfected with either empty vector or kinase
domain construct, and treated with rapamycin (200 nM, 12 h) where indicated before analysis for p62 levels. Right: quantiﬁcation of experiments where bars
represent mean+s.e.m. (n ¼ 3); ∗P , 0.05. (E) Transfected cells were treated as indicated before staining with lysotracker. Bars represent mean+s.e.m.
(n ¼ 3); ∗P , 0.05.
520 Human Molecular Genetics, 2012, Vol. 21, No. 3events were found with rapamyin. In either case, these data
suggest that TORC1 inhibitors may prove beneﬁcial in treating
neurodegenerative events related to LRRK2.
LRRK2-expressing cells display a decrease in the number
of lysosomes with acidic pH. Given that acidic pH is only
lost in a fraction of lysosomes, further studies are warranted
to elucidate whether there exists a correlation between
the affected lysosomal subpopulation and the localization
of endogenous NAADP receptors. In either case, the
LRRK2-mediated effects on lysosomal pH are mild and do
not result in a lysosomal proteolysis phenotype (62,63), and
under basal conditions and in the absence of additional
protein aggregation stress, these LRRK2-mediated effects do
not affect cell survival.
NAADP is the most powerful endogenous Ca
2+ mobilizing
compound known to date. It seems to invoke an initial trigger
release from acidic stores which is then ampliﬁed by Ca
2+-
induced Ca
2+ release from the ER mediated by Ins3P receptors
(47). TPCs are the likely target receptors for NAADP. Whilst
still poorly characterized ion channels, they display a broad
tissue distribution, indicating that they might play a general
role in the mobilization of acidic Ca
2+ stores. The observation
that a speciﬁc NAADP antagonist blocks all LRRK2-mediated
effects analysed here, together with the observed interaction
between LRRK2 and TPC2, suggests a molecular mechanism
for LRRK2 function involving TPC2 on acidic stores. In this
context, LRRK2 may regulate TPC2 channel behaviour,
even though additional effects at the level of NAADP gener-
ation cannot be excluded. To our knowledge, this is the ﬁrst
report which links the effects of LRRK2 through an effect
on NAADP receptors. Thus, NAADP receptors may represent
possible new targets for interventions for familial and sporadic
PD linked to abnormal LRRK2 activity.
MATERIALS AND METHODS
Plasmid constructions
To generate the LRRK2 kinase domain-GFPemd construct
(kinase-GFPemd), the human LRRK2 kinase domain (aa
1844–2143) was PCR ampliﬁed using full-length LRRK2 as
template, with EcoRI/BamHI sites on either end. VAMP2-
GFPemd (64) was digested with EcoRI/BamHI to release
VAMP2, and the PCR-ampliﬁed kinase domain cloned
in-frame with the GFPemd at the C-terminal end.
To generate the LRRK2 kinase domain pCMV construct
(pCMV-kinase), human LRRK2 kinase domain (amino acid
1844–2143) was PCR ampliﬁed using full-length LRRK2 as
template, with SacI/BamHI sites on either end. pCMV-VAMP2
(64) was digested with SacI/BamHI to release VAMP2, and
religated with the digested, PCR-ampliﬁed kinase domain.
To generate the full-length human LRRK2 pCMV vector
(pCMV-ﬂLRRK2), pGEMT-LRRK2 was digested with
SacII/MluI to release ﬂ-LRRK2. Quick Change Site Directed
Mutagenesis was performed with the empty pCMV vector to
introduce a SacII site 5′ to the MluI site, followed by digestion
of the vector with SacII/MluI and introduction of ﬂLRRK2.
K1906M and G2019S mutations were introduced into all re-
spective vectors by Quick Change Site Directed Mutagenesis,
and the identity of all constructs veriﬁed by direct sequencing
of the entire coding regions.
The double-myc-tagged, full-length wild-type and mutant
human LRRK2 constructs were kindly provided by
M. Cookson (NIH, Bethesda, USA). Full-length constructs
were transformed in Stbl3 E. coli, and DNA prepared using
the BACMAX DNA Puriﬁcation Kit (Epicentre Biotechnolo-
gies, Madison, USA).
N-terminally myc-tagged constructs for wild-type, domin-
ant-negative and constitutively active AMPKa1, as well as
N-terminally myc-tagged constructs for wild-type and
dominant-negative AMPKa2 were kindly provided by
D. Carling (MRC, Imperial College London, UK). Bcl-2 and
its organelle-speciﬁc mutants were kindly provided by
M. Ja ¨a ¨ttela ¨ (Institute of Cancer Biology, Danish Cancer
Society, Denmark) and D.W. Andrews (McMaster University,
Hamilton, Ontario, Canada). Human TPC1-mRFP, TPC1-
L273P-mRFP and TPC2-mRFP have been previously
described. The L265P mutation in TPC2-mRFP was generated
by Quick Change Site Directed Mutagenesis and veriﬁed by
direct sequencing.
The tandem-tagged LC3 construct mCherry-EGFP-LC3B
(human) was kindly provided by T. Johansen (University of
Tromsø, Norway), and EGFP-LC3 (rat) was provided by
T. Yoshimori (National Institute for Basic Biology, Okazaki,
Japan) and J. Oliver (Institute of Parasitology and Biomedi-
cine ‘Lo ´pez-Neyra’, CSIC, Granada, Spain). The G120A
mutation was introduced into both tagged LC3 constructs by
Quick Change Site-Directed Mutagenesis (Stratagene) and
veriﬁed by direct sequencing.
Figure 9. Model for the LRRK2-mediated events identiﬁed in this study. It is
proposed that LRRK2 directly or indirectly activates NAADP-receptors (such
as TPC2), resulting in an increase in cytosolic Ca
2+.C a
2+ efﬂux from acidic
stores may lead to a concomitant increase in lysosomal pH. The cytosolic in-
crease in Ca
2+ may result in Ca
2+-induced Ca
2+ release from ER stores, and
activation of CaMKKb, followed by activation of AMPK and an increase in
autophagosome numbers. These LRRK2-mediated events seem to sensitize
cells to cell death in the presence of additional compounds interfering with
proteasomal degradation. Detection methods and/or tools used in this study
to analyse and modulate the indicated events are depicted in red. dn, dominant-
negative.
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NAADP-AM and NED-19 were synthesized as previously
described (54,65). Torin was a generous gift of D. Sabatini
(Whitehead Institute for Biomedical Research, Cambridge,
USA). 3-MA (3-methyladenine), NH4Cl, baﬁlomycin A1,
E-64d, pepstatin A, nigericin, trichostatin A, dantrolene, puro-
mycin and ionomycin were from Sigma. STO-609 (7-oxo-
7H-benzimidazo[2,1-a]benz[de]isoquinoline-3-carboxylic acid)
and L690,440 (1-[(4-hydroxyphenoxy)ethylidene]bis
[[phosphinylidyne bis(oxymethylene)]-2,2-dimethylpropanoate)
were from Tocris Bioscience (Missouri, USA). Compound
C, cycloheximide and MG-132 were from Calbiochem.
BAPTA-AM was from Invitrogen, rapamycin was from LC
Laboratories (Woburn, USA) and chloroquine was a generous
gift from L. Ruiz Pe ´rez (Institute of Parasitology and Biomedi-
cine ‘Lo ´pez-Neyra’, CSIC, Granada, Spain).
Cell culture, transfection and cell lysis
Unless otherwise indicated, experiments were performed in
HEK293T cells, which were cultured as previously described
(66). Where indicated, experiments were also performed in
neuroendocrine PC12 cells, which were cultured and trans-
fected as previously described (64). Cells at 70–80%
conﬂuency were transfected using Lipofectamine 2000
(Invitrogen) according to manufacturer’s speciﬁcations for
4 h, followed by addition of fresh medium. Single transfec-
tions were performed using 3.5 mg of plasmid of interest and
10 ml of Lipofectamine 2000. For double-transfections,
2.5 mg of each plasmid was used, and for triple-transfections,
1.7 mg of each plasmid was employed. The DNA ratio for
co-transfections in the case of full-length LRRK2 constructs
was 1:5, using a total of 10 mgo fD N A .
Cells were treated with the indicated concentrations of com-
pounds and for the indicated times, and cell extracts prepared
24 or 48 h after transfection. Cells were rinsed once in ice-cold
PBS, followed by resuspension in 1 ml of lysis buffer per
100 mm dish (160 ml of lysis buffer per well of a 6-well
plate) (1% SDS in PBS containing 1 mM PMSF, 1 mM
Na3VO4 and 5 mM NaF). Extracts were boiled for 5 min, soni-
cated and centrifuged at 13 500 rpm for 10 min at 48C. Protein
concentrations of supernatants were estimated using the BCA
assay (Pierce). Whenever possible, extracts were immediately
resolved by SDS–PAGE without repeated freeze-thaws, as the
latter was found to decrease detection of some phosphorylated
proteins.
Immunoﬂuorescence staining and confocal microscopy
Transfected cells were re-plated at a 1:3 ratio onto coverslips
and processed for immunocytochemistry 24 or 48 h after trans-
fection. Lysotracker DND-99, LysoSensor Green DND-189
and Bodipy 493/503 dyes were used essentially according to
manufacturer’s instructions (Invitrogen). Fixed cells were
mounted using ProLong Gold AntiFade mounting medium
(Invitrogen), and images acquired on a Leica TCS-SP5 con-
focal microscope using a ×100 HCX PL APO CS 1.4 oil
UV objective. Images were collected using single excitation
for each wavelength separately [488 nm Argon Laser line
and a 500–545 nm emission band pass; 543 nm HeNe Laser
line and a 556–673 nm emission band pass; 405 nm UV
diode and a 422–466 nm emission band pass (12.5% inten-
sity)]. Ten to ﬁfteen image sections of selected areas were
acquired with a step size of 0.3 mm, and z-stack images ana-
lysed and processed using Leica Applied Systems (LAS
AF6000) image acquisition software. The same laser intensity
was used for image acquisition of individual experiments.
Co-localization analysis was performed using Leica Applied
Systems (LAS AF6000) image acquisition software, adjusting
thresholds to 28% for each channel.
Primary antibodies included a mouse monoclonal
anti-LAMP2 antibody (1:50; Santa Cruz Biotechnology), a
mouse monoclonal anti-p62 antibody (1:50; BD Transduction
Laboratories), a mouse monoclonal anti-myc antibody
(1:10000, Sigma) and a rabbit polyclonal anti-GFP antibody
(1:1000; Abcam). Secondary antibodies included goat anti-
rabbit or goat anti-mouse AlexaFluor-405-conjugated second-
ary antibody (1:100; Invitrogen), AlexaFluor-488-conjugated
secondary antibody (1:1000; Invitrogen) or AlexaFluor-555-
conjugated secondary antibody (1:1000; Invitrogen).
For detection of apoptosis, ﬁxed cells were mounted using
mounting medium containing DAPI (Vector Laboratories)
and visualized on a Zeiss microscope using a ×100
oil-immersion objective. For each experiment, an average of
100 cells from random ﬁelds was quantiﬁed, and condensed
or fragmented nuclei scored as apoptotic cells. Occasionally,
apoptotic cells were also quantiﬁed using the DeadEnd Fluoro-
metric TUNEL System (Promega) according to manufac-
turer’s speciﬁcations (Promega).
Quantitative image analysis
Autophagic activity was evaluated by quantifying the
average number of GFP–LC3 punctae per cell. For this
purpose, z-stacks of random ﬁelds of cells were captured at
×100 magniﬁcation on a confocal microscope. The number
of GFP–LC3 punctae per cell was either obtained by
manual counts performed by an observer blinded to condi-
tion, or more regularly using an NIH ImageJ macro called
GFP–LC3 (13). Alternatively, random ﬁelds of transfected
cells were imaged on a Zeiss microscope using a ×100
oil-immersion objective by an individual blinded to the
experimental conditions, and the number of GFP–LC3
punctae per cell counted manually. Whilst the decreased
resolution results in identiﬁcation of overlapping or clustered
punctae as a single large puncta, and thus will underestimate
the number of GFP–LC3 punctae per cell, the relative
changes observed using this determination were similar to
those using the high-resolution analysis described above.
For all determinations of LC3–GFP punctae per cell,
between 30 and 50 randomly chosen transfected cells were
analysed per experiment and condition. For quantiﬁcation
of yellow and red mCherry-EGFP–LC3 (td-tag-LC3)
punctae, pictures were captured at ×100 magniﬁcation on
a confocal microscope, and the number of yellow and red
punctae analysed as described above from 40 randomly
chosen transfected cells per experiment and condition.
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Transfected cells were collected, resuspended in HEPES-
buffered media and ﬁltered through a 50 mm ﬁlter before
FACS sorting. Sorted cells were ﬁxed with 4% paraformalde-
hyde, 0.1% glutaraldehyde in 0.1 M cacodylate buffer contain-
ing 3 mM CaCl2 and 7.5% sucrose for 15 min at room
temperature. Fixed cells were washed and pelleted, then cell
pellets were cut into small cubes and mixed to randomize
the sample. Samples were stained with reduced osmium tetra-
oxide, dehydrated and embedded in resin. Sections ( 80 nm)
were examined with an FEI TECNAI BioTWIN electron
microscope. Random cells were imaged.
To calculate relative volume densities, Photoshop software
was used to combine separate images to obtain a complete
view of each cell. Autophagic structures were recognized
according to their morphological characteristics. A counting
gridwassuperimposedonimagesatarandomoffsetandintersec-
tions were scored according to the underlying structures, using
the ImageJ plug-ins Grids and Cell Counter (NIH, Bethesda,
MD, USA). The relative volume density of each structure was
calculated by dividing the number of intersections counted for
each category by the number counted for the whole cell.
Western blotting
ProteinswereresolvedbySDS–PAGE,transferredontopolyvi-
nylidene diﬂuoride membranes (Hybond, GEHealthcare) and
probedwithprimaryantibodiesovernightat48C.Thefollowing
antibodies were employed: a rabbit polyclonal anti-phospho-
ACC (Ser79), a rabbit monoclonal anti-phospho-AMPKa
(Thr172) (40H9), a rabbit monoclonal anti-AMPKa, a rabbit
polyclonal phospho-S6 (S235/236), a rabbit polyclonal
phospho-p70 S6 kinase (Thr389), a rabbit polyclonal p70 S6
kinase, a rabbit monoclonal phospho-4E-BP1 (T37/46)
(236B4) and a rabbit polyclonal 4E-BP1. All those antibodies
were from Cell Signaling Technology, and used at a dilution
of 1:500. Additional antibodies included a mouse monoclonal
anti-p62 (1:500; BD Transduction Laboratories), a mouse
monoclonal anti-LAMP2 (H4B4) (1:200; Santa Cruz Biotech-
nology), a mouse monoclonal anti-LAMP1 (H4A3) (1:200;
Santa Cruz Biotechnology), a goat polyclonal anti-cathepsin
D antibody (1:100; Santa Cruz Biotechnology), a mouse mono-
clonal anti-cathepsin L antibody (1:100; BD Biosciences), a
mouse monoclonal anti-LC3 (1:500; MBL, Japan), a rabbit
polyclonal anti-LC3 (1:500; Cell Signaling Technology), a
rabbit polyclonal anti-GFP (ab6556) (1:500; Abcam), a mono-
clonalanti-bclantibody(ab694)(1:10000;Abcam),amonoclo-
nal anti-tubulin antibody (clone DM1A) (1:5000; Sigma), a
rabbit polyclonal anti-pan-14-3-3 antibody (K-19) (1:500;
Santa Cruz Biotechnology), a rabbit monoclonal anti-LRRK2
antibody (MJFF2, 1:500;Epitomics) ora mouse monoclonal C-
terminal anti-LRRK2 antibody (N241A/34, NeuroMab,
UCDavis, USA). Membranes were washed and incubated with
secondary antibodies [anti-rabbit HRP-conjugated antibody
(1:2000) or anti-mouse HRP-conjugated antibody (1:2000)
(Dako Cytomation)] for 90 min at room temperature, followed
by detection using ECL reagents (Roche). Unless otherwise
indicated, 50 mg of cell extracts were resolved on MiniProtean
Gels (BioRad Laboratories), whilst for phospho-p70 S6
kinase, phospho-4E-BP1, LC3 and p62, 150 mg of cell extracts
were resolved on large PROTEAN II gels (BioRad Laborator-
ies), and westerns developed with enhanced ECL reagents
(Roche). Upon chemiluminescence detection, a series of timed
exposures were undertaken to ensure that densitometric ana-
lyses were performed at exposures within the linear range.
Films were scanned, and QuantityOne (Biorad) was employed
for densitometric analysis.
Immunoprecipitation
Transfected cells were washed in chilled PBS and pelleted by
centrifugation. Pellets were resuspended in IP buffer (1 ml/
10 cm dish) containing 1% NP-40, 50 mM Tris/HCl, pH 7.4,
150 mM NaCl, phosphatase inhibitor cocktails 2 and 3
(Sigma) and protease inhibitor cocktail (Roche) and lysates
centrifuged at 13500 rpm for 10 min at 48C. Protein concen-
tration of supernatants was estimated using a BCA assay,
and 1 mg total protein was subjected to immunoprecipitation
with either anti-GFP (5 mg, Abcam) or anti-LRRK2 (10 mg,
N138/6, NeuroMab, UCDavis, USA) antibodies. For immuno-
precipitations, lysates were incubated with antibodies for 1 h
at 48C, followed by addition of protein G or protein A Seph-
arose beads and incubation overnight. Beads were washed
ﬁve times with IP buffer followed by elution with SDS
sample buffer and heating at 508C for 3 min prior to separation
by SDS-PAGE.
Statistical analysis
Data are expressed as means+s.e.m., and the signiﬁcance of
differences was assessed using unpaired t-tests. Differences
were accepted as signiﬁcant at the 95% level (P , 0.05).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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